A target for potential cancer drugs may, in fact, worsen disease
In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyrosine phosphatase 2 or more briefly, Shp2.
Nov 9, 2021
0
53